-
公开(公告)号：US20150079613A1
公开(公告)日：2015-03-19
申请号：US14453268
申请日：2014-08-06
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/626 , C07K2317/76 , G01N33/6863 , G01N2333/4716 , G01N2333/485 , G01N2333/522 , G01N2333/5412 , G01N2333/5421 , G01N2333/5434 , G01N2333/545 , G01N2333/57 , G01N2333/70503 , G01N2333/70525 , G01N2333/70539 , G01N2333/7151 , G01N2333/7452 , G01N2333/75 , G01N2333/775 , G01N2333/8139 , G01N2333/8146 , G01N2333/974 , G01N2800/226 , G01N2800/347 , G01N2800/50 , G01N2800/52
摘要： The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
摘要翻译： 本公开提供了生物标志物蛋白质，其浓度或活性水平的变化与非典型溶血性尿毒症综合征（aHUS）相关，或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险，诊断高血压，确定受试者是否正在经历第一次急性呈现的HUS，监测进展或减轻HUS，和/或监测对治疗的反应 补体抑制剂或优化这种治疗。
-
公开(公告)号：US20210285964A1
公开(公告)日：2021-09-16
申请号：US17161783
申请日：2021-01-29
摘要： The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
-
公开(公告)号：US20160033514A1
公开(公告)日：2016-02-04
申请号：US14827693
申请日：2015-08-17
发明人： Susan Faas MCKNIGHT , Roxanne COFIELL , Yan YAN
IPC分类号： G01N33/574 , G01N33/50
CPC分类号： G01N33/57492 , A61K39/39558 , A61K2039/505 , A61K2039/545 , A61K2039/57 , C07K16/2803 , G01N33/5091 , G01N33/5094 , G01N33/57484 , G01N33/68 , G01N2333/70517 , G01N2333/70596 , G01N2800/52
摘要： The present disclosure relates to anti-CD200 antibodies (e.g., variant anti-CD200 antibodies having decreased or no effector function) and to biomarkers for use in a variety of diagnostic and therapeutic methods, e.g., determining whether a human has been administered one or more of the antibodies at a dose sufficient to induce a desired immunomodulatory effect in the human and/or selecting an appropriate dosing schedule for a patient.
-
公开(公告)号：US20170023590A1
公开(公告)日：2017-01-26
申请号：US15287162
申请日：2016-10-06
CPC分类号： G01N33/6893 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/626 , C07K2317/76 , G01N33/6863 , G01N2333/4716 , G01N2333/485 , G01N2333/522 , G01N2333/5412 , G01N2333/5421 , G01N2333/5434 , G01N2333/545 , G01N2333/57 , G01N2333/70503 , G01N2333/70525 , G01N2333/70539 , G01N2333/7151 , G01N2333/7452 , G01N2333/75 , G01N2333/775 , G01N2333/8139 , G01N2333/8146 , G01N2333/974 , G01N2800/226 , G01N2800/347 , G01N2800/50 , G01N2800/52
摘要： The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
摘要翻译： 本公开提供了生物标志物蛋白质，其浓度或活性水平的变化与非典型溶血性尿毒症综合征（aHUS）相关，或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险，诊断高血压，确定受试者是否正在经历第一次急性呈现的HUS，监测进展或减轻HUS，和/或监测对治疗的反应 补体抑制剂或优化这种治疗。
-
公开(公告)号：US20160154009A1
公开(公告)日：2016-06-02
申请号：US15013833
申请日：2016-02-02
CPC分类号： G01N33/6893 , A61K2039/505 , C07K16/18 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/626 , C07K2317/76 , G01N33/6863 , G01N2333/4716 , G01N2333/485 , G01N2333/522 , G01N2333/5412 , G01N2333/5421 , G01N2333/5434 , G01N2333/545 , G01N2333/57 , G01N2333/70503 , G01N2333/70525 , G01N2333/70539 , G01N2333/7151 , G01N2333/7452 , G01N2333/75 , G01N2333/775 , G01N2333/8139 , G01N2333/8146 , G01N2333/974 , G01N2800/226 , G01N2800/347 , G01N2800/50 , G01N2800/52
摘要： The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.
摘要翻译： 本公开提供了生物标志物蛋白质，其浓度或活性水平的变化与非典型溶血性尿毒症综合征（aHUS）相关，或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险，诊断高血压，确定受试者是否正在经历第一次急性呈现的HUS，监测进展或减轻HUS，和/或监测对治疗的反应 补体抑制剂或优化这种治疗。
-
-
-
-
搜索结果
5 条记录 (耗时 0.02 秒)
